![benign findings benign findings](https://adc.bmj.com/content/archdischild/100/6/599/F1.large.jpg)
How is the diagnosis of benign follicular nodule made? For that reason, the term benign follicular nodule is used in place of a more specific diagnosis. Most of the time it is not possible for a pathologist to tell the difference between these conditions when examining tissue removed by fine needle aspiration. The tumour cells are separated from the normal thyroid gland by a thin tissue barrier called a capsule. Follicular adenoma: Follicular adenoma is a non-cancerous type of thyroid tumour.Multiple nodules of varying sizes are typically found in both lobes. Patients with Graves’ disease often have an enlarged thyroid gland. Nodules in Graves disease: Graves is an autoimmune disease associated with increased production of thyroid hormone (hyperthyroidism).Most adenomatoid nodules develop in association with a condition called nodular thyroid hyperplasia.
![benign findings benign findings](https://radiologykey.com/wp-content/uploads/2016/09/A325490_1_En_2_Fig172_HTML.gif)
Adenomatoid nodule: Adenomatoid nodule is a non-cancerous type of growth in the thyroid gland.Another name for this condition is a goiter. It is the most common cause of thyroid nodules in adults. Nodular thyroid hyperplasia: Nodular thyroid hyperplasia is a non-cancerous type of growth involving the thyroid gland.The following conditions can cause a benign follicular nodule: All the conditions in this group are made up of cells that look similar when examined under the microscope. This diagnosis is usually made after a procedure called a fine needle aspiration (FNAB). What is a benign follicular nodule in the thyroid gland?īenign follicular nodule is a term pathologists use to describe a group of non-cancerous conditions in the thyroid gland. If you have any questions about this article or your pathology report, please contact us.
![benign findings benign findings](https://assets.cureus.com/uploads/figure/file/157095/article_river_8dea7e20102d11eba152db9193edab36-Fig-3a.png)
Our data support the policy for discontinuation of routine interval imaging after benign concordant biopsy.About this article: This article was created by doctors to help you read and understand your pathology report for “benign follicular nodule”. CONCLUSIONS: Interval imaging performed <12 months after benign concordant breast biopsy demonstrated a low yield for the detection of breast cancer and resulted in increased health care costs. The cost of detecting a missed cancer with interval imaging after benign concordant biopsy was $41,813.77 in this cohort. Only one breast cancer was identified, representing 0.5 % (95 % confidence interval 0-3.4) of all benign concordant patients undergoing interval imaging. Five (2.7 %) patients had suspicious findings on follow-up imaging. Interval imaging <12 months after benign biopsy was obtained in 182 (54.0 %) concordant patients. Of the remaining 454 patients who did not undergo excision, 337 (74.2 %) had documented radiologic-pathologic concordance. Of 498 patients with benign findings, 44 (8.8 %) underwent surgical excision as a result of discordance, atypia, papillary lesion, or other benign finding. RESULTS: Of 689 patients, 188 (27 %) had malignant pathology, 3 (0.4 %) had nonbreast pathology, and 498 (72.3 %) had benign pathology. Charts were evaluated for documentation of radiologic-pathologic concordance. METHODS: An institutional review board-approved retrospective chart review identified 689 patients who underwent image-guided breast biopsy at Bryn Mawr Hospital between January and December 2010. We hypothesized that interval imaging <12 months after benign concordant biopsy has a low cancer yield and increases health care costs. The value of 6-month interval imaging after benign radiologic-pathologic concordant minimally invasive breast biopsy.īACKGROUND: Current National Comprehensive Cancer Network guidelines recommend repeat imaging 6-12 months after a benign radiologic-pathologic concordant image-guided breast biopsy.